156 related articles for article (PubMed ID: 35078980)
1. Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.
Oliveira JL; Greipp PT; Rangan A; Jatoi A; Nguyen PL
Blood Cancer J; 2022 Jan; 12(1):11. PubMed ID: 35078980
[No Abstract] [Full Text] [Related]
2. Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Matsuo K; Klar M; Mohrbacher AF; Roman LD; Wright JD
Eur J Cancer; 2021 Nov; 157():59-62. PubMed ID: 34487985
[No Abstract] [Full Text] [Related]
3. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
[TBL] [Abstract][Full Text] [Related]
4. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
Nitecki R; Melamed A; Gockley AA; Floyd J; Krause KJ; Coleman RL; Matulonis UA; Giordano SH; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):653-659. PubMed ID: 33736856
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
6. A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
Chiusolo P; Marchetti C; Rossi M; Minnella G; Salutari V; Distefano M; Giammarco S; Metafuni E; Minucci A; Frioni F; Gasbarrino C; Colangelo M; Orteschi D; Fagotti A; Lorusso D; Pagano L; De Stefano V; Scambia G; Sica S
Am J Hematol; 2022 Nov; 97(11):E400-E403. PubMed ID: 36054600
[No Abstract] [Full Text] [Related]
7. PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.
Tinker AV
Lancet Haematol; 2021 Feb; 8(2):e97-e99. PubMed ID: 33347815
[No Abstract] [Full Text] [Related]
8. SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.
Fabiani E; Falconi G; Fianchi L; Criscuolo M; Leone G; Voso MT
Haematologica; 2014 Sep; 99(9):e152-3. PubMed ID: 24907359
[No Abstract] [Full Text] [Related]
9. Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
Zhu J; Tucker M; Wang E; Grossman JS; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1137-e1141. PubMed ID: 28780018
[No Abstract] [Full Text] [Related]
10. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
Ma Z; Sun XM; Lu WC; Zhao ZX; Xu ZM; Lyu JY; Zhao P; Liu LH
ESMO Open; 2021 Feb; 6(1):100033. PubMed ID: 33444891
[No Abstract] [Full Text] [Related]
13. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome.
Iurlo A; Mecucci C; Van Orshoven A; Michaux JL; Boogaerts M; Noens L; Bosly A; Louwagie A; Van Den Berghe H
Cancer Genet Cytogenet; 1989 Dec; 43(2):227-41. PubMed ID: 2598167
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related myelodysplastic syndrome/acute myeloid leukemia M2 and translocation (8;21).
Sakugawa M; Kojima K; Kaneda K; Masuda K; Dansako H; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M; Tanimoto M
Ann Hematol; 2001 Dec; 80(12):763-6. PubMed ID: 11797121
[TBL] [Abstract][Full Text] [Related]
16. Therapy-related myeloid neoplasms.
Czader M; Orazi A
Am J Clin Pathol; 2009 Sep; 132(3):410-25. PubMed ID: 19687318
[TBL] [Abstract][Full Text] [Related]
17. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Kontandreopoulou CN; Diamantopoulos PT; Tiblalexi D; Giannakopoulou N; Viniou NA
Blood Adv; 2021 Nov; 5(22):4794-4805. PubMed ID: 34529761
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
Borthakur G; Estey AE
Curr Oncol Rep; 2007 Sep; 9(5):373-7. PubMed ID: 17706165
[TBL] [Abstract][Full Text] [Related]
19. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
Girard S; Lours C
Am J Hematol; 2023 Oct; 98(10):1665-1666. PubMed ID: 37226864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
